These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6668971)

  • 1. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 7. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L; Vilageliu J; Freixes J
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
    Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of amino acid derivative of clofibric acid (WKLB-5), and theophylline monoester of nicotinic acid (ME1) on the development of experimental atherosclerosis in rabbits.
    Wójcicki J; Jaworska M; Samochowiec L; Hinek A
    Pol J Pharmacol Pharm; 1986; 38(1):77-84. PubMed ID: 3509959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
    Vilageliu J; Freixes J; Giráldez A; Bermejo P; Basi N; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1805-7. PubMed ID: 6274363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 15. Plafibride tolerance trial in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J; López-Delmás FJ
    Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 19. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M; Frohlich J
    Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ; del Rio A; González-Viejo N; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.